Enzymit

Enzymit is developing a cell-free biomanufacturing platform that combines computational enzyme design, deep learning, and high-throughput discovery to enable precise and scalable production of complex molecules.

In addition to enzyme and pathway design, we have built capabilities in fermentation-based enzyme production, process development, downstream processing, and operation of integrated cell-free bioreactor systems. This allows us to support development from early technical validation through process integration and scale-up.

Our technology combines the selectivity of biology with the controllability of chemistry, creating production systems with strong advantages in precision, purity, and process flexibility compared with conventional fermentation and chemical synthesis.

We have validated the platform through kilogram-scale hyaluronic acid production with industrial partners and are advancing toward commercial supply. Beyond HA, we are expanding the platform toward additional bio-based products.

We are interested in collaborations involving industrial biotechnology, advanced biomanufacturing, sustainable production systems, process scale-up, downstream processing, and commercialization. 

The company is currently advancing toward commercial HA supply while expanding its platform to high-value products such as heparin and human milk oligosaccharides (HMOs).

Founded in 2020 and headquartered in Rehovot, Israel, Enzymit is backed by leading investors, including Khosla Ventures and Grove Ventures.